Structure Therapeutics (NASDAQ:GPCR) · earnings miss
Quarter
Q3
EPS estimate to actual
-$0.29→ to -$0.66
Revenue estimate to actual
$50.0M→ to $0.0
At a glance
Key takeaways
01Structure Therapeutics reported Q3 EPS of -$0.66, missing the consensus estimate of -$0.29 by $0.37 per share.
02Revenue missed estimates with a 128% shortfall, though the actual revenue figure was not disclosed in the article.
03The stock trades at $21.73 with a $3.9B market capitalization following the earnings miss.
04EPS misses have widened significantly, worsening from -6.1% in Q1 to -127.6% in Q3 2026.
05Earnings misses of this magnitude typically trigger analyst revisions and can influence institutional investor positioning.
Earnings Results
Structure Therapeutics (NASDAQ:GPCR) reported quarterly earnings results on November 09, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.66, missing the consensus estimate of $-0.29 by $0.37 per share. Revenue came in at , missing the estimate of $50.0M.
Company Overview
Structure Therapeutics's stock moved following the earnings release. The stock currently trades at $21.73 with a market capitalization of $3.9B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
The 128% miss relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Structure Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.